[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.19.31. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1991

Apraclonidine and TimololCombined Effects in Previously Untreated Normal Subjects

Author Affiliations

From the Department of Ophthalmology, University of Umea, Umea, Sweden (Dr Koskela) and the Department of Ophthalmology, Mayo Clinic, Rochester, Minn (Dr Brubaker).

Arch Ophthalmol. 1991;109(6):804-806. doi:10.1001/archopht.1991.01080060068026
Abstract

• Twenty healthy subjects were tested for the aqueous-suppressing effects of the α2-adrenergic agonist apraclonidine hydrochloride. Apraclonidine caused a 30% reduction of mean (±SD) aqueous flow during the daytime from 2.84±0.61 μL/min, similar to what has been observed for β-adrenergic antagonists. Apraclonidine, like acetazolamide and unlike timolol maleate, was able to suppress the aqueous flow of sleeping subjects below the spontaneous nocturnal rate of 1.15±0.40 μL/min to 0.84±0.28 μL/min, a 27% change. When apraclonidine and timolol were given together in the daytime, no clinically significant or statistically significant additive effect was observed. The range of flows with either drug alone or the combination of the two measured from 2 to 4 pm was 1.41 to 1.78 μL/min. This result contrasts with studies of the effect of apraclonidine on patients who have received long-term β-blockers where an additive effect is observed. The lack of an additive effect on flow in previously untreated normal subjects suggests that the two drugs act at least in part via a common pathway.

×